Effective treatment of young patients with pediatric-onset,long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study

Abstract

The objective of the current work is to report the preliminary experience with tacrolimus (TL) administered as a single-dose daily for maintenance therapy of young patients with pediatric-onset, long-standing systemic lupus erythematosus (SLE). Six consecutive patients with long-standing SLE were recruited for a 6-month open-label trial of single-dose-daily administration of tacrolimus (3 mg/day) without dose up of concomitantly administered prednisolone (PDN). TL treatment was started at the time of the most recent flares. Data on the clinical and serologic lupus activity were collected prospectively. The baseline characteristics of the patients were: mean age, 20 years; urinary protein/creatinine ratio, 1.22 ± 1.94; serum C3 level, 70.8 ± 21.2 (normal, 79—152 mg/dL); serum complement hemolytic activity (CH50), 22.2 ± 10.3 (normal, 23—46 U/mL); serum anti-dsDNA antibody titer, 60.4 ± 71.7 IU/mL (normal, < 12.0 IU/mL); serum creatinine, 0.55 ± 0.11 mg/dL; European Consensus Lupus Activity Measurement (ECLAM) index, 5.2 ± 2.6. Despite the gradual tapering of the PDN dose, marked improvement as compared with the baseline values was observed in the ECLAM index examined at one and three months and serological parameters examined at three months after the start of treatment. After a 6-months' therapy, complete response was achieved in all of the patients (serum CH50 value, 27.7 ± 8.3 U/mL; serum anti-dsDNA antibody titer, 28.4 ± 27.9 U/mL and the ECLAM index, 1.2 ± 1.2 (P < 0.05), respectively), except in one patient who showed WHO class V lupus nephritis. No serious adverse effects were observed. These data suggest that TL, even when administered as a single-daily dose, is effective and safe for selected young patients with pediatric-onset, long-standing SLE. However, further studies on a larger number of patients are needed to confirm these results. Lupus (2007) 16, 896—900.

Keywords

adolescents maintenance therapy single-daily-dose administration systemic lupus erythematosus tacrolimus

Get full access to this article

View all access options for this article.

References

Davidson A. , Aranow C.

Pathogenesis and treatment of systemic lupus erythematosus nephritis

Curr Opin Rheumatol 2006; 18: 468—475.

Lehman TJ , Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243—247.

Lai KN , Tang Scw , Mok CC Treatment for lupus nephritis: a revisit. Nephrology 2005; 10: 180—188.

Tanaka H. , Tsugawa K. , Tsuruga K. et al. Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol 2004; 62: 412—417.

Kondo H. , Abe T. , Hashimoto H. et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study . J Rheumatol 2004; 31: 243—251.

Kawai S. , Yamamoto K.

Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients

Rheumatology ( Oxford) 2006; 45: 441—444.

Mok CC , Tong KH , To CH , Siu YP , Au TC Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005 ; 68: 813—817.

Duddridge M. , Powell RJ Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997; 56: 690—692.

Politt D. , Heintz B. , Floege J. , Mertens PR Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus . Clin Nephrol 2004; 62: 49—53.

10.

Maruyama M. , Yamasaki Y. , Sada K. et al. Good response of membranous lupus nephritis to tacrolimus Clin Nephrol 2006; 65: 276—279.

11.

Tse KC , Lam MF , Tang Scw , Tang Cso , Chan TM A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibitor or blockade. Lupus 2007; 16: 46—51.

12.

Mosca M. , Bencivelli W. , Vitali C. , Carrai P. , Neri R. , Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000; 9: 445—450.

13.

Davies TH , Ning YM , Sanchez ER Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and immunosuppressive ligand FK506 . Biochemistry 2005; 44: 2030—2038.

14.

Tanaka H. , Tsugawa K. , Suzuki K. et al. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus Eur J Pediatr 2007 ; 166: DOI:10.1007/s00431-006-0380-0

15.

Tanaka H. , Tsugawa K. , Suzuki K. , Ito E. Renal biopsy findings in children receiving long-term treatment with cyclosporine A given as a single daily dose. Tohoku J Exp Med 2006; 209: 191—196.